Ensysce Biosciences Inc ENSC Shares traded up 21.81% at $0.82 on Wednesday after the company announced the start of the final phase of its Phase 1 study in opioid overdose protection.
What else?
According to Ensysce Biosciences, this key study will be conducted in healthy volunteers by dr Maria Bermudez MDat Quotient Sciences, Miami, Fla.
PF614, a TAAPTM Prodrug of oxycodone, has a number of safety features designed to reduce abuse, including its extended-release profile, which has been shown to reduce “drug addiction” in recreational drug users.
Meanwhile, PF614-MPAR is designed to provide optimal pain relief at prescribed doses.
dr Lynn KirkpatrickCEO of Ensysce, commented: “We are committed to improving the lives of patients living with severe pain by providing safe and effective products. We believe that TAAPTM and MPARTM can be incorporated into many drugs, and our initial focus on pain is just one step in transforming multiple drug classes.”
See also: Why Reed shares are nosediving
“PF614-MPAR is an opioid pain relief product designed to provide two layers of safety, one to reduce abuse and the second to prevent overdose. We believe PF614-MPAR could be the first opioid product to prevent all four common methods of opioid abuse – chewing – such as snuffing, injecting and oral overdose. The current study aims to confirm that our approach to limiting opioid release with our combined oxycodone product PF614-MPAR can save lives,” said Kirkpatrick.
According to data from Gasoline ProENSC has a 52-week high of $47.00 and a 52-week low of $0.59.
[ad_2]
Source story
